Food-packed tables and endless spirits can present a special challenge for those taking GLP-1 medications like Wegovy, ...

Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

LOS ANGELES, CA / ACCESS Newswire / December 12, 2025 / The landscape of weight management has undergone a seismic shift. Zealthy is one of the fastest-growing telehealth weight-loss platforms in the ...

With foodborne illnesses and changes in Medicare and Medicaid coverage, University of Virginia (UVA) Health experts say never ...

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

Phoenix NP announced a continued rise in patient satisfaction across Arizona, noting that positive feedback has increased as more women seek safe, FDA-approved GLP-1 weight loss medications through ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

The House has spent much of the last two months of this year trying to catch up on its work. It passed 22 bills in one recent ...

LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor ...